Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats

Journal of Hypertension

Volumn 29, Issue 8, 2011, Pages 1613-1623

  Toblli, Jorge E ^a   Cao, Gabriel ^a   Giani, Jorge F ^b   Muñoz, Marina C ^b   Angerosa, Margarita ^a   Dominici, Fernando P ^b  

^a HOSPITAL ALEMÁN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

chronic kidney disease; metabolic syndrome; oxidative stress; blockers

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD31 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE; NEBIVOLOL; NEPHRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOCIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; KIDNEY; KIDNEY FIBROSIS; LIPID BLOOD LEVEL; LONG TERM CARE; METABOLIC SYNDROME X; MICROSCOPY; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; TREATMENT OUTCOME; VASODILATATION; ZUCKER DIABETIC FATTY RAT;

EID: 79960566642     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328349064c     Document Type: Article

References (55)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-1428. (Pubitemid 40523737)
2. Grundy SM.Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47:1093-1100.
3. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286:H1597-H1602. (Pubitemid 38525443)
4. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997; 50:191-197.
5. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006; 38:64-80. (Pubitemid 43177789)
6. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16:2134-2140. (Pubitemid 41716445)
7. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23:599-622. (Pubitemid 35191625)
8. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18:655-673. (Pubitemid 30406736)
9. Forde P, Scribner AW, Dial R, Loscalzo J, Trolliet MR. Prevention of hypertension and renal dysfunction in Dahl rats by alpha-tocopherol. J Cardiovasc Pharmacol 2003; 42:82-88. (Pubitemid 36791354)
10. Midaoui AE, Elimadi A, Wu L, Haddad PS, de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens 2003; 16:173-179. (Pubitemid 36293060)
11. Chen YF, Cowley AW Jr, Zou AP. Increased H(2)O(2) counteracts the vasodilator and natriuretic effects of superoxide dismutation by tempol in renal medulla. Am J Physiol Regul Integr Comp Physiol 2003; 285:R827-R833. (Pubitemid 37169145)
12. Cirillo P, Sautin YY, Kanellis J, Kang DH,Gesualdo L, Nakagawa T, Johnson RJ. Systemic inflammation, metabolic syndrome and progressive renal disease. Nephrol Dial Transplant 2009; 24:1384-1387.
13. Friedman EA, Friedman AL. Is there really good news about pandemic diabetic nephropathy? Nephrol Dial Transplant 2007; 22:681-683. (Pubitemid 46351668)
14. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 2006; 6:479-483. (Pubitemid 44896409)
15. Stuveling EM, Bakker SJ, Hillege HL, de Jong PE, Gans RO, de Zeeuw D. Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 2005; 20:497-508. (Pubitemid 40378417)
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
17. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14:203-209.
18. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000; 342:969-970. (Pubitemid 30177059)
19. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42:474-480. (Pubitemid 37237341)
20. Malminiemi K. Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 1995; 9:295-304.
21. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14:489-494. (Pubitemid 26161099)
22. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in noninsulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955-959. (Pubitemid 27255798)
23. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236. (Pubitemid 39473160)
24. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11:552-563.
25. Sule SS, Frishman W. Nebivolol: new therapy update. Cardiol Rev 2006; 14:259-264. (Pubitemid 44298023)
26. Gupta S, Wright HM. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 2008; 26:189-202.
27. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23:589-596. (Pubitemid 40684718)
28. Toblli JE, Cao G, Casas G, MazzaON. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats. Am J Hypertens 2006; 19:1226-1232. (Pubitemid 44856250)
29. Whaley-Connell A, Habibi J, Johnson M, Tilmon R, Rehmer N, Rehmer J, et al. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol 2009; 30:354-360.
30. Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992; 19:I110-I115.
31. Kasiske BL, Cleary MP, O'Donnell MP, Keane WF. Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 1985; 106:598-604.
32. Magil AB. Tubulointerstitial lesions in young Zucker rats. Am J Kidney Dis 1995; 25:478-485.
33. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57:167-182. (Pubitemid 30227764)
34. Gassler N, Elger M, Kranzlin B, Kriz W, Gretz N, Hahnel B, et al. Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat. Kidney Int 2001; 60:106-116. (Pubitemid 32587545)
35. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest 2002; 82:25-35. (Pubitemid 34072643)
36. Toblli JE, Cao G, Giani JF, Angerosa M, Dominici FP, Gonzalez-Cadavid NF. Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res 2010; 34:20-33.
37. Laight DW, Desai KM, Anggard EE, Carrier MJ. Endothelial dysfunction accompanies a pro-oxidant, pro-diabetic challenge in the insulin resistant, obese Zucker rat in vivo. Eur J Pharmacol 2000; 402:95-99. (Pubitemid 30625315)
38. Pannirselvam M, Verma S, Anderson TJ, Triggle CR. Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db (/() mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol 2002; 136:255-263. (Pubitemid 34587672)
39. Brodsky SV, Gealekman O, Chen J, Zhang F, Togashi N, Crabtree M, et al. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res 2004; 94:377-384. (Pubitemid 38240730)
40. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant 2009; 24:2384-2391.
41. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150:76-85. (Pubitemid 16258399)
42. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010; 152:159-166.
43. Fujii H, Kono K, Nakai K, Goto S, Komaba H, Hamada Y, et al. Oxidative and nitrosative stress and progression of diabetic nephropathy in type 2 diabetes. Am J Nephrol 2010; 31:342-352.
44. Attia DM, Ni ZN, Boer P, Attia MA, Goldschmeding R, Koomans HA, et al. Proteinuria is preceded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats. Kidney Int 2002; 61:1776-1787. (Pubitemid 34437931)
45. Cominacini L, Fratta Pasini A, Garbin U, Nava C, Davoli A, Criscuoli M, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003; 42:1838-1844. (Pubitemid 37433667)
46. Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahioglu M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008; 23:853-859. (Pubitemid 351767560)
47. Varagic J, Ahmad S, Brosnihan KB, Habibi J, Tilmon RD, Sowers JR, Ferrario CM. Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol. Am J Nephrol 2010; 32:557-566.
48. Garcia PJ, Tamega OJ, Soares JC, Piffer CR, Zorzetto NL. Contribution to the study of the styloid prominence in the posterior tympanic cavity. Anat Anz 1982; 151:247-254. (Pubitemid 12111700)
49. Habibi J, Hayden MR, Sowers JR, Pulakat L, Tilmon RD, Manrique C, et al. Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology 2011; 152:659-668.
50. Pires MJ, Rodriguez-Pena AB, Arevalo M, Cenador B, Evangelista S, Esteller A, et al. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. J Hypertens 2007; 25:2486-2496. (Pubitemid 350060388)
51. Kakoki M, Hirata Y, Hayakawa H, Suzuki E, Nagata D, Nishimatsu H, et al. Effects of vasodilatory antihypertensive agents on endothelial dysfunction in rats with ischemic acute renal failure. Hypertens Res 2000; 23:527-533.
52. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107:2747-2752. (Pubitemid 36667251)
53. Georgescu A, Pluteanu F, Flonta ML, Badila E, Dorobantu M, Popov D. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 2005; 508:159-166. (Pubitemid 40169915)
54. Essawy M, Soylemezoglu O, Muchaneta-Kubara EC, Shortland J, Brown CB, el Nahas AM. Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 1997; 12:43-50. (Pubitemid 27046200)
55. Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 2009; 5:203-211.